WHO, the Global Fund, and medical malpractice in malaria treatment

Lancet

Volumn 363, Issue 9404, 2004, Pages 237-240

  Attaran, Amir ^a   Barnes, Karen I ^b   Curtis, Christopher ^c   D'Alessandro, Umberto ^d   Fanello, Caterina I ^c   Galinski, Mary R ^e   Kokwaro, Gilbert ^f   Looareesuwan, Sornchai ^g   Makanga, Michael ^h   Mutabingwa, Theonest K ⁱ   Talisuna, Ambrose ^j   Trape, Jean François ^k   Watkins, William M ^l  

^a ROYAL INSTITUTE OF INTERNATIONAL AFFAIRS   (United Kingdom)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^e Malaria Foundation International   (United States)

^f UNIVERSITY OF NAIROBI   (Kenya)

^g MAHIDOL UNIVERSITY   (Thailand)

^h KEMRI WELLCOME TRUST RESEARCH PROGRAMME   (Kenya)

ⁱ E African Netwk Monitoring A   (Tanzania)

^j MINISTRY OF HEALTH   (Uganda)

^k INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (Senegal)

^l UNIVERSITY OF LIVERPOOL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ANTIVIRUS AGENT; ARTEMISIN; CHLOROQUINE; FANSIDAR; INSECTICIDE; LEPROSTATIC AGENT; TUBERCULOSTATIC AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BED NET; CHILDHOOD; CHINESE MEDICINE; DEATH; DEVELOPING COUNTRY; DISEASE TRANSMISSION; DRUG FORMULATION; ENDEMIC DISEASE; GAMETOCYTE; HEALTH CARE COST; HOSPITAL ADMISSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEPROSY; MALARIA; MALARIA CONTROL; MALPRACTICE; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; TREATMENT FAILURE; TUBERCULOSIS; WORLD HEALTH ORGANIZATION;

EID: 9144242399     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)15330-5     Document Type: Note

References (43)

1. Nabarro D.N., Tayler E.M. The Roll Back Malaria campaign. Science. 280:1998;2067-2068.
2. WHO, UNICEF. Africa malaria report 2003. WHO doc WHO/CDS/MAL/ 2003·1093. Geneva: WHO, 2003. http://mosquito.who.int/amd2003/amr2003/ pdf/amr2003.pdf (accessed Jan 1, 2004).
3. WHO. Position of WHO's Roll Back Malaria Department on malaria treatment policy. http://www.emro.who.int/rbm/WHOPositionStatement.pdf (accessed Dec 15, 2003).
4. The efficacy of antimalarial monotherapies, sulphadoxine-pyrimethamine and amodiaquine in East Africa: implications for sub-regional policy. Trop Med Int Health. 8:2003;860-867.
5. Mutabingwa T., Nzila A., Mberu E., et al. Chlorproguanildapsone for treatment of drug-resistant falciparum malaria in Tanzania. Lancet. 358:2001;1218-1223.
6. Trape J.F., Pison G., Preziosi M.P., et al. Impact of chloroquine resistance on malaria mortality. C R Acad Sci III. 321:1998;689-697.
7. Korenromp E., Williams B.G., Gouws E., Dye C., Snow R.W. Measuring trends in childhood malaria mortality in Africa: a new assessment of progress toward targets based on verbal autopsy. Lancet Infect Dis. 3:2003;349-358.
8. Trape J.F. The public health impact of chloroquine resistance in Africa. Am J Trop Med Hyg. 64:(suppl):2001;12-17.
9. WHO. Access to antimalarial medicines: improving the affordability and financing of artemisinin-based combination therapies. WHO doc WHO/CDS/MAL/2003·1095. Geneva: WHO, 2003.
10. Zucker J.R., Ruebush TK 2nd, Obonyo C., Otieno J., Campbell C.C. The mortality consequences of the continued use of chloroquine in Africa: experience in Siaya, western Kenya. Am J Trop Med Hyg. 68:2003;386-390.
11. Artesunate combinations for treatment of malaria: meta-analysis. Lancet. 363:2004;9-17.
12. Adjuik M., Agnamey P., Babiker A., et al. Amodiaquine-artesunate versus amodiaquine for uncomplicated Plasmodium falciparum malaria in African children a randomized, multicentre trial. Lancet. 359:2002;1365-1372.
13. Premji Z, Falade CO, Makanga M, et al. Efficacy of co-artemether (artemether-lumefantrine), 6-dose regimen, in African infants and children with acute uncomplicated falciparum malaria. Abstract 36. American Society of Tropical Medicine and Hygiene, 52nd Annual Meeting and Centennial Celebration. Philadelphia: December 3-7, 2003.
14. Zambia National Malaria Control Centre. In vivo efficacy studies conducted in patients under five years of age with acute uncomplicated Plasmodium falciparum malaria in the sentinel sites of Zambia. 2003; unpublished.
15. Kshirsagar N.A., Gogtay N.J., Moorthy N.S., et al. A randomized, double-blind, parallel-group, comparative safety and efficacy trial of oral co-artemether versus oral chloroquine in the treatment of acute uncomplicated Plasmodium falciparum malaria in adults in India. Am J Trop Med Hyg. 62:2000;402-408.
16. Tjitra E., Suprianto S., Currie B.J., Morris P.S., Saunders J.R., Anstey N.M. Therapy of uncomplicated falciparum malaria: a randomized trial comparing artesunate plus sulfadoxine-pyrimethamine versus sulfadoxine-pyrimethamine alone in Irian Jaya, Indonesia. Am J Trop Med Hyg. 65:2001;309-317.
17. Marquiño W., Huilca M., Calampa C., et al. Efficacy of mefloquine and a mefloquine-artesunate combination therapy for the treatment of uncomplicated Plasmodium falciparum malaria in the Amazon basin of Peru. Am J Trop Med Hyg. 68:2003;608-612.
18. van Vugt M., Looareesuwan S., Wilairatana P., et al. Artemether- lumefantrine for the treatment of multidrug-resistant falciparum malaria. Trans R Soc Trop Med Hyg. 94:2000;545-548.
19. Hien T.T., Dolecek C., Mai P.P., et al. Oihydroartemisinin-piperaquine against multidrug resistant Plasmodium falciparun malaria in Vietnam: randomised cminical trial. Lancet. 363:2004;18-20.
20. White N.J., Nosten F., Looareesuwan S., Watkins W.M., Marsh K., Snow R.W. Averting a malaria disaster. Lancet. 353:1999;1965-1967.
21. van Agtmael M.A., Eggelte T.A., van Boxtel C.J. Artemisinin drugs in the treatment of malaria: from medicinal herb to registered medication. Trends Pharmacol Sci. 20:1999;199-205.
22. Roll Back Malaria Partnership Secretariat. Scaling-up for sustainable impact: Roll Back Malaria strategic orientations 2004-08 (Oct 16, 2003). http://www.rbm.who.int/cmc_upload/0/000/016/915/strategic_orientation.pdf (accessed Nov 12, 2003).
23. McIntosh HM. Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine for treating uncomplicated malaria (Cochrane Review). In: The Cochrane Library, Issue 4, Oxford Update Software, 2003.
24. McNeil D. New drug for malaria pits US against Africa. New York Times, May 28, 2002.
25. Global Fund. The framework document of the Global Fund to Fight AIDS, Tuberculosis and Malaria. Available at http://www.theglobalfund.org/en/files/ publicdoc/Framework_uk.pdf (accessed Nov 8, 2003).
26. Global Fund. Projected procurements of HIV/AIDS and malaria products for proposal rounds 1-3. Presented at UNICEF, Copenhagen, Oct 20, 2003.
27. Talisuna AO, Bloland P, D'Alessandro U. History, dynamics and public health importance of malaria parasite resistance. Clin Microbiol Rev (in press).
28. Yamey G. Malaria researchers say global fund is buying "useless drug" BMJ. 327:2003;1188.
29. WHO. Antimalarial drug combination therapy: report of a WHO Technical Consultation, 4-5 April 2001. Document WHO/CDS/RBM/2001·35. Geneva: World Health Organization, 2001.
30. E-mail from GFATM to the authors. November 14, 2003.
31. Kenya GFATM proposal. http://www.theglobalfund.org/search/docs/ 2KENM_244_173_full.doc (accessed Nov 23, 2003).
32. Ethiopia GFATM proposals. http://www.theglobalfund.org/search/docs/ 2ETHM_235_182_full.doc (malaria-specific) and http://www.theglobalfund.org/ search/docs/2ETHH_234_0_full.doc (general) (accessed Nov 8, 2003).
33. Uganda GFATM proposal. http://www.theglobalfund.org/search/docs/ 2UGDM_287_0_full.doc (accessed Nov 8, 2003).
34. WHO. Scaling up antiretroviral therapy in resource-limited settings: guidelines for a public health approach. Geneva: World Health Organization, 2003.
35. WHO. Treatment of tuberculosis: guidelines for national programs. 3rd edition. Document WHO/CDS/TB 2003·313. Geneva: World Health Organization, 2003.
36. GFATM Technical Review Panel. Uganda (review form). http://www.aidspan. org/globalfund/grants/round2/trp-uganda-mal.htm (accessed Nov 23, 2003).
37. GFATM. Serve on the Technical Review Panel (advertisement). http://www.theglobalfund.org/en/jobs/trp_application.asp (accessed Nov 29, 2003).
38. WHO. The use of antimalarial drugs: report of a WHO Informal Consultation, Nov 13-17, 2000. Document WHO/CDS/RBM/ 2001·33. Geneva: World Health Organization, 2001.
39. WHO. 3 million HIV/AIDS sufferers could receive antiretroviral therapy by 2005. Press release WHO/58. Geneva: World Health Organization, July 9, 2002.
40. Gupta R., Cegielski J.P., Espinal M.A., et al. Increasing transparency in partnerships for health - introducing the Green Light Committee. Trop Med Int Health. 7:2002;970-976.
41. Yamey G. Global health agencies are accused of incompetence. BMJ. 321:2000;787.
42. Donor responsibilities in rolling back malaria. Lancet. 356:2000;521.
43. WHO. Establishment of a new unit: TB/HIV and drug resistance. WHO information note 18/2003. Geneva: World Health Organization, Dec 5, 2003.